To a non-expert, this seems to be a neat new tool: Google can now create and export isochrones (maps of the space within a given travel time from a point) from a given point. Here's the space within 30 minutes of Seattle's trauma hospital (Harborview), for ex. developers.google.com/maps/documen...

Interesting idea for people with iron deficiency who struggle to take iron pills! @shematologist.medsky.social, have you heard of this? www.tiktok.com/@by.eunicel/...

bc fatigue, nausea, dizziness, anxiety, and hair loss shouldn't be your whole personality #anemia #anemiasymptoms #irondeficiency #lowiron

TikTok video by by.eunicel

tiktok.com

There's been a lot of excitement about GLP1s in breast cancer - mostly on the basis of retrospective data. How to sort through it all? And how might GLP1s affect survivorship issues like lymphedema & cardiovascular risk? Read on below ⬇️ @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications | JCO Oncology Practice

Breast cancer is increasingly recognized as an obesity-associated disease, with obesity linked to higher risk of postmenopausal estrogen receptor–positive disease and adverse outcomes across stages. A...

ascopubs.org

New federal data shows that as of February, 19.2 million people were signed up for ACA plans, down about 3 million as enhanced premium subsidies were allowed to expire. That number will surely grow as more people find they can't pay much higher out-of-pocket premiums. aspe.hhs.gov/reports/aca-...

Managing bone health in breast cancer survivors on aromatase inhibitors: comprehensive review out now in JCO OP! @jessicaallenmd.bsky.social ascopubs.org/doi/full/10....

Nice editorial @thewonkologist.bsky.social & Dr. Nancy Keating about revisiting our priors re: Medicare Advantage for cancer care. While there is reason to be cautious and investigate, current data on MA vs traditional medicare in cancer is far from conclusive. ascopubs.org/doi/10.1200/...

For unpaid #carers, earning more does not always lead to economic security. Motivated by the recent #Carer's #Allowance scandal, I have a new working paper @usociety.bsky.social on how much insecurity carers experience, for how long, who's most exposed and why: osf.io/preprints/so... 1/2

Never mind!

Hannah R. Abrams@hannahrabrams.bsky.social · last mo.

Does anyone know what happens if an entire group’s games all end in draws?

Does anyone know what happens if an entire group’s games all end in draws?

Olúfẹ́mi O. Táíwò@olufemiotaiwo.bsky.social · last mo.

good to see the energy of Egypt's press but seems like composure lacking so far, as likely to concede as to equalize at this rate

Did not know cancer centers can technically now bill for patient navigation. I agree with the patients interviewed here: navigation is extremely high-value, and also I do not think it should be behind a paywall. ascopubs.org/doi/10.1200/...

Waiting for clinical teams to order NGS slows down turnaround time by 2 weeks on average. It's time for insurance companies & cancer centers to work together & set up automatic pipelines in these situations, so patients don't have a long anxious wait to start treatment. ascopubs.org/doi/10.1200/...

Timely, this recent piece in JCO Oncology Practice @ascocancer.bsky.social seems aimed towards helping private practice oncologists understand the implications of selling to their practice to PE firms: ascopubs.org/doi/10.1200/...

From Burnout to Buyout: Private Equity's Growing Appeal in Oncology | JCO Oncology Practice

ascopubs.org

Aaron Mitchell@thewonkologist.bsky.social · 2mo ago

I appreciated this thoughtful commentary on our recent (surprisingly "negative") study of private equity's effect on cancer care. I would summarize as: we looked only at one form of harm, and other potential harms have not been excluded. academic.oup.com/jnci/advance...

Midjourney has announced they're developing a full-body 60 second "ultrasonic CT". I want better & cheaper imaging. But the idea that: 50K scanners x 720 min x 30d = 1 billion scans/mo Seems totally unaware of supply/demand, logistical constraints of getting people in/out, & privacy concerns

On the #ASCO26 hot topics of KRAS and toxicity: systematic review & meta-analysis in JCO OP of sotorasib dosing shows trend to improved PFS with LOWER dosing. Less toxicity -> longer time on-treatment? @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

Key #desmoid tumor takeaways from RINGSIDE presentation (varegacestat) #ASCO26 #sarcoma today: - ORR 55.7%, remainder largely shrunk but under 30% - Quick time to pain improvement - only 4 weeks in many - 80% need for dose reduction primarily d/t diarrhea

JCO OP at #ASCO26: Follow up yesterday's session, "Cancer Care in Times of Crisis and in Immigrant and Displaced Populations." Full case discussion out now @jco-asco.bsky.social: ascopubs.org/doi/10.1200/...

#ASCO26 Abstract 12160: impressive effort to review charts of n = 848 patients for whether corticosteroids for irAE → worse cancer outcomes. Adds to/confirms existing literature in this area suggesting the concern is really with high doses.

Simultaneous publications drop today! JCO & JCO OP @jco-asco.bsky.social release first sim pubs of #ASCO26 today. Here are the first 3: 1. Anselamimab in AL amyloid 2. Titrating or not for first dose taxanes 3. Adding BCG to chemo + immunotherapy in MIBC

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials

PURPOSEIn immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their…

ascopubs.org

What can we tell folks w/ taxane-induced peripheral neuropathy after early-stage cancer re: whether it will recover? @SWOG.org 1714, #ASCO26 abs 12117: - Of 1321 pts, 553 had TIPN at end of tx. - 48.5%, it improved - 33.8% didn't change - 17.7% worsened @drdawnhershman.bsky.social #survivorship

Tips for fellows going to their first #ASCO26 (as I prepare to go to my whole of... second): Google "mccormick place floor plan" and pick your favorite version of the map to save to your phone. I'm sure the blue 3D one works for some people, but it does not for me! 😂

It's not in your head: prior auth has increased over the past 10 years in oncology. (Though not as much as other specialties.) @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

We have a lot of mechanisms to prevent OVER dosing of chemotherapy. This week in #JCOOP, Dr. Ruth Choa & colleagues outline a case in which an EMR error led a patient to receive an UNDER dose -only 50%- for 4/8 cycles of curative-intent treatment. @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

340B as it exists now is crucial to oncology care. In JCO OP this month, @ascocancer.bsky.social releases updated policy recommendations for reform of the program: ascopubs.org/doi/10.1200/... @jco-asco.bsky.social

#Biomarker data present in EHR were missing in 80%-100% of #FHIR extracts though demographic registry variables were highly concordant, highlighting gaps in real-world data extraction/exchange methods & risks of relying on RWD w/o validation academic.oup.com/jamiaopen/ar... #MedSky #OncSky #CanSky

Follow the data: tracking data quality and completeness in oncology real-world data

Lay Summary. Cancer research is rapidly evolving, with growing emphasis on genomic data and biomarker testing to guide treatments. In this study, we manual

academic.oup.com

The detection of another circulatory system in the human body could have enormous scientific implications.

Inside the Interstitium, the Human Body’s Hidden Pathways

The detection of another circulatory system in the human body could have enormous scientific implications.

nyti.ms

Go @avrahamcoopermd.bsky.social!

Mina Kimes@minakimes.bsky.social · 3mo ago

This was so interesting!

I'd like to thank Reviewer #2 for asking why my colleagues and I bothered to assess cancer care-related financial toxicity among cancer survivors who were no longer in active treatment. That is, in fact, the period when the impacts are most felt.

honestly cure stories is a really hard space to work in because they take off so easily

Genuine question for bluesky health info folks: Last month there were 2 pancreatic cancer studies shared, largely by press release: - RASolute 302, phase 3 study of 500 people, in which a daily pill DOUBLED survival for people whose cancer progressed after chemo - mRNA vaccine phase 1... (1/4)

Out now at Cancer Control: our qualitative study of the intersection of financial and travel burdens among rural-dwelling cancer survivors (who screened positive for financial toxicity)